Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics to $100 from $95 and keeps a Buy rating on the shares. The analyst came way positively from Axsome’s Q2 report, saying it featured a top-line beat that was driven by strong performances from its two commercial assets, Auvelity and Sunosi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXSM:
- DraftKings upgraded, Home Depot downgraded: Wall Street’s top analyst calls
- Axsome Therapeutics price target lowered to $180 from $190 at H.C. Wainwright
- Axsome Therapeutics upgraded to Neutral from Underperform at BofA
- Piper upgrades Axsome to Overweight on commercial expansion
- Axsome Therapeutics upgraded to Overweight from Neutral at Piper Sandler